Elevated Lp(a) contributes to pro-inflammatory gene expression of monocytes in both healthy subjects and CVD patients. Potent Lp(a)-lowering reduced the pro-inflammatory state of circulating monocytes.

Relationships between inflammation, LDL-c and CV risk have not much changed compared to findings from two decades ago. Those with highest levels of IL-6 or hsCRP and highest levels of LDL-c have highest risk of MACE.

Inclisiran, an siRNA against PCSK9, did not result in adverse effects on measures of inflammation, immune activation and platelets. No clinical immunogenicity AEs were observed.

In an analysis of two large U.S. cohorts, higher olive oil intake was associated with lower risk of major CVD and CHD risk compared to those consuming olive oil <1 per month.

This viewpoint article draws attention towards acute and possible long-term implications of coronavirus infections, such as COVID-19, on the cardiovascular system.

Lp(a) meeting Jeffrey Kroon presents his study on inflammatory mechanisms driving CV risk in patients with high Lp(a) levels and a potential new strategy to reduce atherogenesis in these patients.

Several studies suggest that a healthy Nordic diet, which differs from the Mediterranean diet in that it contains berries and uses canola instead of olive oil, has beneficial effects, but the evidence is limited.

Patients with ACS who received prasugrel before PCI, showed less endothelial dysfunction and platelet aggregation, while those on clopidogrel and ticagrelor did not, nor did treatment after PCI.

Erin Bohula explains which determinants of residual CV risk we nowadays know and presents study results on how to target these.

AHA 2019 The COLCHICINE-PCI trial investigated whether a single dose of the anti-inflammatory agent colchicine, given prior to PCI, resulted in reduced vascular inflammation and myocardial injury after PCI.

AHA 2019 Pradhan was the discussant of the COLCOT trial. She put the results in the broader perspective of managing inflammation as a means to lower CV risk.

AHA 2019 Dr. Tardif summarizes the study design and results of the COLCOT trial, in which colchicine treatment was found to lower a composite endpoint in patients soon after MI.